Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1200 participants.

Also called NCT07719894

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07719894
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07719894. Randomized; no masking; primary purpose treatment. Start 2026-05-06 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes
Acronym
Cilo-Asa
Condition
Type 2 Diabetes Mellitus (T2DM)
Condition
Atherosclerosis
Intervention (Drug)
Cilostazol
Intervention (Drug)
Aspirin
Lead sponsor
Seoul National University Bundang Hospital (class: other)

Record details

Record id
cardio:ct-nct07719894
Content hash
b17ef3cf2c15f67ac43e7499b3528957d076347d7d501921ca0573c700391d16